Forest Sees Two Potential Fibromyalgia Indications For Milnacipran
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest has two potential indications for its fibromyalgia therapy milnacipran, President & Chief Operating Officers Ken Goodman said during the firm's July 19 investor call
You may also be interested in...
Forest Snaps Up SNRI, Builds Pipeline
Potential successor to Lexapro may be safer than stalled fibromyalgia drug milnacipran.
Forest Snaps Up SNRI, Builds Pipeline
Potential successor to Lexapro may be safer than stalled fibromyalgia drug milnacipran.
Forest/Cypress Fibromyalgia Treatment Milnacipran Aims To Take On Pfizer’s Lyrica With More Robust Data
Cypress Chief Business Officer tells the DAILY that use of a more stringent composite endpoint could provide advantage for milnacipran over Lyrica and other potential treatments.